Stevanato Group SpA（STVN）のニュースとイベントSTVNStevanato Group SpA

Company Narrows 2026 Revenue View to EUR1.26B-EUR1.28B

Narrows 2026 revenue view to EUR1.26B-EUR1.28B from EUR1.26B-EUR1.29B.

Stevanato Reports Q2 Revenue of €302.0M

Reports Q2 revenue EUR302.0M vs. EUR280.0M last year. CEO Franco Stevanato commented, "Results were in line with our expectations with 8% topline growth driven by 10% growth at constant currency rates in our BDS Segment. We recently achieved a significant commercial milestone for our Drug Delivery Systems business and our proprietary DDS products. A customer recently received regulatory approval in several European countries for a liraglutide-based therapy that incorporates Stevanato Group's Alina pen injector platform. This important customer project also embeds our world-class cartridge technology into the Alina pen platform, harnessing the power of our integrated capabilities."

Stevanato Group Receives Marketing Authorization for Alina Injector in Europe

Stevanato Group announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains.